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is a myeloproliferative disorder characterized by clonal expansion of hematopoiesis and marrow fibrosis. Previous results from our group have shown an increased production of t w o potent fibrogenic factors also involved in the regulation of primitive hematopoietic cells, namely transforming growth factor-p1 (TGF-p1) and basic fibroblast growth factor (bFGF), in patients with MMM. It is likely t o assume that the myeloproliferation characteristic of this disease may result from an abnormal proliferation of CD34' hematopoietic progenitors. Thus, we were particularly concerned in studying the gene and protein expression of these cytokines and their receptors in CD34+ progenitors purified from the peripheral blood of MMM patients by using semiquantitative reverse transcriptase-polymerase chain reaction and immunolabeling methods. Our data showed that the expression of TGF-YELOFIBROSIS with myeloid metaplasia (M"), also named idiopathic myelofibrosis or agnogenic myeloid metaplasia, is a chronic myeloproliferative disorder featured by marrow fibrosis, leukoerytroblastosis, and extramedullary hematopoiesis with hepatosplenomegaly.' An increased number of circulating hematopoietic precursors, including pluripotent (colony-forming unit-granulocyte, erythroid, monocyte, megakaryocyte [CFU-GEMM]) and committed (colony-forming unit-granulocyte-macrophage [CFU-GM], burst-forming unit-erythroid [BFU-E], and colony-forming unit-megakaryocyte [CFU-MK]) progenitor^,"^ is observed in patients. It probably results from cell migration from the fibrotic bone marrow to the circulation.' Data from splenectomized patients have suggested that spleen and liver also may play a role in the committed progenitor increase. 4 ,' A number of findings have provided evidence that the myeloproliferation resulted from a clonal amplification of primitive stem cells. On the contrary, fibroblast proliferation appeared to be polyclonal, thus suggesting that myelofibrosis expression of TGF-p type II receptor is significantly decreased in such cells, as compared with CD34+ cells from healthy subjects. Regarding bFGF, the very low expression of the cytokine and its type I and II receptors detected in normal CD34+ cells contrasts with that observed in patients' CD34+ cells, which is significantly higher. Our results might be a clue for a better understanding of the mechanism(s) involved in the dysregulation of hematopoiesis in MMM. Actually, the increased expression of bFGF and its receptors associated with the reduction of the TGF-p binding receptor in CD34+ progenitors from MMM patients might facilitate the expansion of hematopoietic progenitors, not only by stimulating their growth and/or survival, but also by overcoming negative regulatory signals.
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was a reactive process."." Although the pathogenesis of bone marrow fibrosis still remains unclear, some observations have suggested that the increased reticulin network was secondary to the abnormal activation of fibroblasts by cytokines released from megakaryocytes and platelets." The potential role of the platelet-derived growth factor (PDGF) in the pathogenesis of MMM was first highlighted by Castro-Malaspina," who showed that homogenates of megakaryocytes stimulated human bone marrow fibroblasts to divide and secrete collagens. We have recently shown that the expression of transforming growth factor-p1 (TGF-01) in patients with MMM was significantly increased in circulating peripheral blood mononuclear cells (PBMC) characterized as cells of the megakaryocytic lineage."^" Besides PDGF and TGFp. the possible involvement in myelofibrosis of another potent fibrogenic factor, the basic fibroblast growth factor (bFGF), has been recently suggested by the observation of an increased production of bFGF in patients with MMM (M.C. Martyr&, manuscript submitted) and in a murine experimental model (MC. Le Bousse-Kerdilhs, unpublished data).
Both TGF-p and bFGF are members of multifunctional polypeptide families that regulate cell growth and differentiation.l7." These cytokines are produced by a wide variety of cells, including hematopoietic and stromal cells."~*' Among their numerous biologic effects, including their potent fibrogenic activity,"." TGF-01 and bFGF are powerful regulators of hematopoiesis by selectively acting on primitive hematopoietic stem cell g r o~t h .~~,~*~*~ By using antisense TGF-01 oligonucleotides, it has been shown that the TGF-p1 gene was expressed in early CD34' hematopoietic progenitors and negatively regulated their cycling status." Recent studies have shown that the suppressive effect of TGF-,8 1 on primitive CD34' hematopoietic cells could be abrogated by bFGF." Furthermore, bFGF has been shown to enhance the colony-stimulating activity of stem cell factor (SCF), interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), or erythropoietin (Epo) on more committed cells such as granulomacrophagic, erythroid. or 273  62  72  89  310  715  79  345   21  2  2  15  2  3  13  4 Abbreviations: Hb, hemoglobin; WBC, white blood count.
megakaryocytic progenitors by synergizing with these growth factor^'^.'^ and to stimulate myelopoiesis in longterm bone marrow culture^.^'
Because myelofibrosis with myeloid metaplasia is characterized by fibrosis and myeloproliferation, the previously reported high levels of TGF-P l I5,l6 and the recent finding of an increased production of bFGF (M.C. Martyr&, manuscript submitted) in patients, together with the fact that both growth factors are fibrogenic agents and act on the primitive hematopoietic progenitor regulation, prompted us to study the expression of TGF-Pl, bFGF, and their receptors in CD34' progenitor cells purified from patients' peripheral blood. Our results indicated that, when compared with normal CD34+ progenitors, TGF-P1 expression is not altered in patients' CD34+ cells, in contrast with the expression of bFGF, which is significantly increased. Furthermore, in CD34+ progenitor cells from MMM patients, whereas the expression of bFGF type I and type I1 receptors is also significantly augmented, the expression of TGF-P type I1 receptor, which binds ligand, is decreased.
MATERIALS AND METHODS

Patients
Because myelofibrosis precludes successful recovery of bone marrow cells, blood samples from 8 patients with M" have been analyzed. Their clinical and hematologic characteristics are listed on Table 1 . Diagnosis was established according to the Polycythemia Vera Study Group clinical and hematologic criteria. The patients were not receiving chemotherapy at the time of the study and during the last 2 months. The mean age of the MMM patients studied was 70 2 8.5 years ( Table 1) .
Because it has been suggested that, in MMM patients, the circulating progenitor rise might result from an increased inflow of progenitors from the bone marrow into the blood, we have performed controls on bone marrow samples obtained from 8 healthy individuals undergoing hip prosthesis surgery (mean age, 68 ? 7 years). We have also purified CD34+ cells from peripheral blood leukocytes obtained from the leukopheresis of 2 hematologic normal volunteers; however, investigations on these samples were limited by the low recovery of cells. Informed consent was provided for patients and healthy donors.
Cell Preparation
All samples were collected on preservative-free heparin. Mononuclear cells were isolated by centrifugation on Ficoll-Hypaque (density, 1.077 g/mL; Pharmacia, Orsay, France). Light-density mononuclear cells were washed several times in phosphate-buffered saline containing 1 mmoVL EDTA (PBSEDTA) to avoid platelet aggregation, resuspended at a concentration of 5 X lo6 cells/mL in RPM1 1640 medium supplemented with 10% fetal calf serum (FCS) and incubated overnight in plastic culture flasks at 37°C with 5% CO2 in air to remove accessory adherent cells.
Nonadherent cells were added to soybean agglutinin (SBA)-coated flasks (CELLector-SBA; AIS, Santa Clara, CA) for 1 hour at room temperature according to the manufacturer's instructions. The nonadherent SBA-cells were removed and washed with PBS. Nonspecific fixation was blocked by incubating SBA-cells with 0.5% (wtl vol) heat-inactivated purified human Ig (Sandoz globulin; Sandoz, Basel, Switzerland) for 15 minutes at room temperature. Hematopoietic progenitors express CD34 antigen, which allows them to be purified. CD34' progenitors were then enriched by incubation on anti-CD34 antibody (ICH3) -coated CELLector flask (AIS) for 1 hour at room temperature. Nonadherent cells (SBA-CD34-) were eliminated by at least seven washes with PBS. The adherent CD34' cells were recovered by incubation in Iscove's modified Dulbecco's medium (IMDM) containing 10% FCS for 1 hour at 37"C, gentle scrapping, and centrifugation.
Antigen Expression Analysis by Flow Cytometry
Multiparameter analysis of purified cells for cell surface antigen expression was performed as follows. Cells (2. RT. Single-stranded cDNA was synthesized from the whole RNA pellet using Moloney's murine leukemia virus (M-MLV) RT and random hexamers as primers. Briefly, 1 pg RNA was mixed with 25 nmol of each dNTP (Bioprobe), 100 pmol of random hexamers (PdN6; Boehringer Mannheim, Meylan, France), 125 U of human placenta ribonuclease inhibitor (HPFU; Amersham, Les Ulis, France), and 200 U of M-MLV RT (GIBCO-BRL, Cergy-Pontoise, France) in a reverse buffer containing MgClz (6.7 mmoVL), (NH4)*S04 (16.6 mmoVL), Tris HCI (67 mmoK), pH 8.8, in a final volume of 20 pL. The mixture was incubated for 30 minutes at 42"C, heated for 5 minutes at 9 4 T , and stored at -80°C until used.
PCR. Semiquantification of gene expression for TGF-Dl, bFGF, and their corresponding type I and I1 receptors was performed after coamplification and normalization with the p2 microglobulin internal control sequence. The nucleotide sequences of primers used are summarized in Table 2 .
PCR was performed on each cDNA sample with an automatic oil. Preliminary experiments were performed to determine the conditions in which cDNAs were amplified in the linear region of the PCR reaction curve. Once these conditions were set up, after an initial denaturation at 94°C for 5 minutes, amplification was performed during 35 cycles composed of denaturation at 94°C for 50 seconds, annealing at 57°C for 50 seconds, and extension at 72°C for 20 seconds. cDNAs from human lung adenocarcinoma A549 cells and, for bFGF RH, breast carcinoma T47D cells were used as positive controls for PCR. Negative controls were the product of RT where RNA was omitted.
The PCR products were visualized on a 2% agarose gel by ethidium bromide staining and analyzed on a 7% polyacrylamide gel. The expression level for each transcript was evaluated by calculating the ratio of TGF-PI, bFGF, and their receptors on P 2 microglobulin signals either after hybridization with internal P' ' oligonucleotide probes specific for each amplified sequence and analysis using a phosphorimager (Molecular Dynamics, Mountain View, CA) or after ethidium bromide staining by densitometric scanning using a video camera (Imager; Appligene, Illkirch, France) and analysis using Image 14461 1 Macintosh software. The results comparing the expression levels of transcripts in CD34' cells from patient blood or normal bone marrow were represented as curves of cumulative frequencies.
Cellular Imrnunodetection of TGF-PI. bFGF, and Their Receptors
TGF-PI and bFGF were detected in cytocentrifuged CD34' cells, after fixation with PBS 4% paraformaldehyde, by an overnight labeling at 4°C with a chicken antihuman TGF-01 antibody (40 pg/mL; R&D Systems Europe, Abington, UK) or a goat antihuman bFGF antibody (10 pg/mL; R&D Systems Europe), respectively, followed by a subsequent incubation with a rabbit antichicken antibody (70 pg/mL; Dako, Copenhagen, Denmark) and staining with a tetramethylrodamine isothiocyanate (TRITC) goat antirabbit antibody (150 pg/mL; Nordic, The Netherlands) for TGF-PI or a subsequent labeling with a TRITC rabbit antigoat antibody for bFGF (diluted 1:40; Nordic, Le Perray-en-Yveline, France).
TGF-0 type I1 receptors (TGF-P RII) were localized in cytocentrifuged CD34' cells after fixation with methanol-acetone (vol/vol) for I O minutes at -20°C and incubation with a rabbit antihuman TGF-P RI1 antibody (25 pg/mL; Santa Cruz Biotechnology, Inc, Santa
Cruz, CA) overnight at 4°C. bFGF receptors (type I and 11) were detected after methanol-acetone fixation and incubation either with a mouse monoclonal antihuman bFGF RI antibody (50 pg/mL; Santa Cruz Biotechnology, Inc) or a rabbit polyclonal antihuman bFGF RI1 antibody (SO pg/mL; Santa Cruz Biotechnology, Inc). After three washes with PBS 1% BSA, cells were incubated for 2 hours at room temperature in the dark with a TRITC goat antirabbit antibody (IS0 pg/mL; Nordic) for TGF-P RII; for bFGF receptors, cells were incubated with a PE goat antimouse antibody for bFGF RI (diluted I :2S; Southern Biotechnology Associates, Inc, Birmingham. AL) or a PE goat antirabbit antibody (diluted 1: IO; Caltag, Le Perray-enYveline, France) for bFGF RII.
For immunofluorescence studies, the specificity of the different antibodies used was confirmed on positive Dami and CCL64 cell lines. In all experiments, nonspecific labeling was avoided by preincubating the slides with serum or Igs from the same species as that of the fluorescent antibody. Negative controls were performed by replacing the primary antibody with nonimmune Ig from the different species. Cells for bFGF and their receptors were examined and photographed using an inverted Leico Fluovert microscope (LeitzFluover, GMBH, Germany) equipped with a 3CCD Sony color video printer (Mitsubishi Electric Corp, Tokyo. Japan).
Assay for TGF-PI and bFGF Proteins and Bioactivities in CD34' Cell Supernatants
CD34+ cells from patients and healthy donors were washed and incubated, without any stromal cell support, in serum-free or 10% FCS supplemented IMDM at a concentration of 5 X IOh cells/mL for 24 hours at 37°C in a S% CO2 atmosphere in air. The supernatants were collected and used respectively for TGF-PI and bFGF protein detection by specific and high sensitivity sandwich enzyme-linked immunosorbent assay (ELISA) following the manufacturer's instructions (Quantikines for human TGF-P1 and bFGF; R&D Systems Europe). Endogenous production of TGF-P1 and bFGF by CD34' cells was also assayed by testing the effect of anti-TGF-P1 or anti-bFGF neutralizing antibodies on the proliferative capacity of these cells. For that purpose, 2,000 to 4.000 CD34' cells from S normal donors or 5 MMM patients were cultivated for 7 to 15 days at 37°C in 200 growth factors including 100 U/mL IL-3, 100 U/mL GM-CSF, and 2 U/mL SCF in the presence of 1 p g h L of anti-TGF-P1 or antibFGF antibodies (R&D Systems, Europe) or of control nonimmune Igs. For each CD34+ sample, cultures were made in triplicate wells. In some experiments, CD34' cells were cultivated in serum-free conditions. TGF-P bioactivity in CD34+ cell supernatants was also assayed using the specific growth inhibition assay on CCL64 cells, as previously de~cribed'~; before bioassay, the samples were acid-activated.
Statistical Analysis
Mean comparison were performed with the nonparametric statistical test of Mann-Whitney. Significant differences were detected if P 5 .05.
RESULTS
CD34+ Cells Pur$ed From Blood of MMM Patients and Normal Bone Marrow Express Similar CD34, CD38, and CD33 Antigen Levels
As shown in Table 3 , the purity of the CD34+ cells recovered from the peripheral blood of MMM patients as well as from normal bone marrow samples was greater than 97% and, in the majority of the samples, was equivalent to 98.5% to 99%. The expression level of the CD34 antigen was equally high in cells purified from normal or MMM subjects (mean fluorescence intensity, 23.3 t 5.1 arbitrary units [AU] v 24.8 t 9.9 AU). Furthermore, the percentage of positive cells and the levels of CD38 and CD33 antigen expression were comparable in MMM and normal bone marrow CD34+ populations ( Table 3 ). The percentage of HLA-DR positive cells was similar in CD34+ cells purified either from normal bone marrow or blood of MMM patients; however, the HLA-DR antigen expression level was slightly increased in CD34+ cells from such patients. In normal blood samples, the purity of the CD34+ cells was approximately 80%. Analysis of the CD34 expression level in these cells showed that two populations could be distinguished: one expressing a similarly high CD34 level than that of MMM blood or normal bone marrow purified cells and the other expressing a lower but significant CD34 antigen level ( Table 3) . The CD34hi8h population isolated from normal blood also expressed CD38, CD33, and HLA-DR antigens; furthermore, similarly to CD34h'gh cells isolated from normal bone marrow or MMM patients, they did not express CD19 antigen. In comparison, the CD34'"" population did not express or expressed low CD33, but was positive for CD19 antigen (3.5 t 0.3 AU) .
In all samples, the immature phenotype of the purified CD34' cells was confirmed on cytospin smears according to the following criteria: (1) cytologic aspect of undifferentiated blasts after staining with May-Griinwald-Giemsa (Fig 1 and  Table 4 ) and (2) their negativity to Sudan black and myeloperoxidase reactions. Besides, the absence of contaminating platelets was also checked in CD34' cell preparations after Giemsa staining and gpIIbIIIa labeling. As shown on Fig 2A and B , TGF-P1 mRNA was detected TGF-P1 mRNA expression was heterogeneous (0.745 and bFGF transcript (Fig 2C and D) was undetectable or very weakly expressed in CD34' from normal bone marrow but was more highly expressed in CD34' cells from the majority (6B) of MMM patients samples (mean transcript levels on all samples. 0.007 z 0.01 3 I' 0.058 2 0.049: P = .01). No bFGF mRNA was detected in CD34' cells purified from both samples of normal peripheral blood. As shown on curves of cumulative frequencies, TGF-P R type I (TGF-,B RI) and type 11 (TGF-P RH) transcripts were detected in CD34' cells from all patients and healthy donors (Fig 3B and D) . Semiquantification of the TGF-0 RIIIP2 microglobulin gene expression ratio showed that the mean level of TGF-P RI1 mRNA was significantly decreased in CD34' progenitors from MMM blood (0.55 I z 0.185) compared with CD34' from normal bone marrow (0.875 2 0.358; P = .03). Figure 3C shows the results of PCR products for TGF-P RI1 in 4 representative MMM or normal subjects. A similar difference in the level of TGF-P RI1 mRNA was observed between MMM CD34' cells and the two samples from normal peripheral blood (0.803 and 2.107). In contrast, comparison of TGF-P RI mRNA levels in CD34' cells purified from normal or MMM subjects did not show any significant difference (Fig 3A and B) . Figure 4A and C shows PCR products for bFGF RI and RI1 in 4 representative MMM or normal subjects: in Fig 4 9 and D, the results of such PCR analysis in a l l the patients and normal subjects studied are expressed as curves ofcumulative frequencies.
10).
Controls
CD34' Cells From M M M Prrtiettts Express Higher
bFGF receptor type I (bFGF RI) and type I1 (bFGF RH) mRNAs were undetectable or weakly expressed in normal CD34" cells regardless of whether they were purified from bone marrow (Fig 4) or from blood. In contrast, all CD34' samples from MMM patients expressed bFGF RI and RI1 mRNAs (Fig 4B and D) . The mean transcript levels of these genes were significantly higher in CD34' cells isolated from MMM patients than from normal bone marrow (0.238 t 0.242 v 0.010 2 0.015, P = .02 for bFGF RI. and 0.404 t 0.366 V 0.125 t 0.207. P = .04 for bFGF RII). Using an anti-TGF-P1 antibody. the peptide was detected within the cytoplasm of a few number of CD34' cells ( 5 10%) regardless of whether the cells were purified from normal or MMM samples (Fig S) . The percentage of TGF-PI -expressing CD34' cells was lower in MMM (Fig SB) than in normal blood (3.2S% 2 1.2%-and 7.5%-I 0.SQ, respectively) but comparable to the percentage observed in normal bone marrow (3.7% -C 1.6%; Fig SA) . The immunostaining intensity appeared comparable in normal and MMM CD34' cells.
CD34' Cells From
bFGF was detected in the cytoplasm of CD34' cells expressing the bFGF transcript (Fig 6) . However, although a weak and granular positivity was detected in the cytoplasm of CD34' cells (45% 2 IO%) in a small number of normal bone marrow samples (Fig 6A) . the immunostaining intensity and the percentage of positive cells @S% t 7%) was signifcantly higher in CD34' cells from the rna.jority of the MMM patients studied (Fig 6B) .
In all experiments. negative controls performed by replacing the primary antibody (anti-TGF-PI or anti-bFGF antibody) with nonimmune Igs showed no significant positivity (Figs SC and 6C. respectively).
Detection of TGF-P I ancl hFCF Proteins ill M M M n r d Nor~nrrl CD34' Cell Cltltltre
Using a growth inhibition assay on CCL64 cells. TGF-P activity could be detected in some samples of culture media from either MMM patients or normal CD34' cells. The levels of TGF-0 were comparable and very low. because they ranged from 100 to IS0 pg/mL. The presence of TGF-0 in CD34' cell supernatants was confirmed using ;I more sensitive sandwich ELISA assay: the values ranged from 170 to 600 pglmL, with no significant difference between normal and MMM cells. We also tested the effect of a neutralizing anti-TGF-01 antibody on the proliferation of CD34' cells. In control experimental conditions. ie. in the presence of growth factors. the doubling time of hematopoietic cells resulting from CD34' progenitor proliferation was 4.25 ? 0.5 days and 2.7 50.2 days for normal and MMM cultures. respectively ( P = .002). After 5 to 7 days of treatment with a neutralizing anti-TGF-01 antibody. the mean percentage of proliferation increase. corresponding to the difference of proliferation between anti-TGF-01 antibody-treated and nonimmune Igs-treated cells. was higher in CD34' cells purified from normal than from MMM patients (44.3% 5 10.6% and 27.5% 5 3.9%. respectively: P = .030). Similar results, confirmed in serum-free cultures. further suggest the presence of TGF-01 in these cultures.
bFGF was difficult to detect in any CD34' culture supernatants. Using a high sensitivity ELISA, we detected bFGF amounts a s low as I to 2 pg/mL for normal CD34' cells and 2 to 6 pglmL for MMM CD34' cells. Concerning bFGF bioactivity, the inhibitory effect of a neutralizing anti-bFGF antibody on the proliferation of CD34' cells in serum-free liquid culture was only detected in 1 MMM patient. suggesting the presence of such biologically active molecules at least in this culture. The presence of TGF-0 R11 in CD34' cells w a s assessed by immunostaining with an anti-TGF-0 RI1 antibody (Fig  7) . TGF-0 RI1 was detected in a small proportion of both normal or MMM CD34' cells: however. the percentage of TGF-0 RH-positive CD34' cells was significantly lower in MMM patients (0.7% 5 0.2%: Fig 7B) than in normal bone marrow ( 12.7% -C 2.5%: Fig 7A) . Moreover. when compared with normal CD34' cells, the staining intensity was weaker in MMM CD34' cells (Fig 7A and B) . Negative controls performed by replacing the primary antibody (anti- For C and F, respectively) .
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RI1 antibodies) with nonimmune Igs showed no significant positivity (Fig 7C) .
bFGF RI and RII Protein Expression Is Higher in CD34+
Cells From MMM Patients Than in Normal CD34+ Cells bFGF receptors type I and I1 could be immunodetected in normal or MMM CD34' cells expressing their corresponding mRNA (Fig 8) . However, only a few normal bone marrow samples expressed both bFGF receptor proteins. In these samples, about 30% of CD34' cells expressed a low level of RI (Fig 8A) and a few CD34' cells (<lo%) expressed a higher level of RI1 (Fig SD) . In contrast, in all MMM patients expressing receptor mRNA, not only did the majority of CD34+ cells express both RI and RI1 proteins (Fig 8B and  E) , but also their labeling intensity was higher than in normal CD34+ cells. Negative controls, performed by replacing the primary antibody (anti-bFGF RI or RI1 antibodies) with nonimmune Igs, did not show any significant immunopositivity (Fig 8C and F) .
DISCUSSION
Our previous results showed an increased production of two potent fibrogenic agents involved in the regulation of primitive hematopoietic progenitors, namely TGF-P and bFGF, in patients with MMM. It is likely to assume that the myeloproliferation characteristic of this disease may result, at least in part, from an abnormal proliferation of circulating CD34+ hematopoietic progenitors (MC. Le Bousse-Kerdilbs et al, manuscript in preparation). We were therefore particularly concerned in comparing the expression of these cytokines and their receptors in CD34' progenitors purified from the peripheral blood of such patients with CD34+ progenitors isolated from normal donors. These CD34+ populations were cytologically and phenotypically comparable. The data reported here point out several findings. First, the expression of TGF-01 is not altered in patients' CD34' cells; in contrast, the expression of TGF-P type I1 receptor is significantly decreased in such cells, as compared with CD34+ cells from blood or bone marrow of healthy subjects. Second, our results show that, despite their low expression, bFGF and its type I (flg) and type I1 (bek) receptors can be detected in CD34' progenitor cells purified from some normal bone marrow samples. Transcripts for these molecules were undetectable or at least weakly expressed in CD34' from normal blood, Third, the low expression of bFGF in normal CD34' cells contrasts with that observed in patients' CD34' cells, which is significantly higher. Finally, both bFGF type I and type I1 receptors appear to be more highly expressed in CD34' cells from patients.
Our findings that TGF-P1 could be detected in the cytoplasm of a small proportion (5 10%) of CD34' cells, regardless of their origin, are in agreement with the results of Li et al,33 who reported that only a subpopulation of early CD34+ progenitors expressed this peptide. TGF-P1 has been shown to act at the early stages of hematopoiesis by negatively regulating the cycling status of primitive progenitor Thus, the enhancing effect of anti-TGF-P1 antibody on the proliferation of CD34+ cells from patients or normal subjects in serum-free culture, and without any stromal cell support, strongly suggests that cells from both sources produce endogenous TGF-P1 and that their responsiveness to this cytokine is mediated via an autocrine loop.
To our knowledge, whereas TGF-P is known to elicit biologic effects in hematopoietic progenitors, protein expression for its receptors has not been reported in human CD34+ cells until now. TGF-P signaling pathway is mediated by two high-affinity transmembrane Serinemhreonine kinases receptors: the type I and type I1 re~eptors.~'.'' A low-affinity TGF-/? type 111 receptor, which does not act in the generation of the signaling pathway but may serve as a reservoir for TGF-0, has also been cloned.3* It has been recently shown by Wrana et a139 that TGF-P binds directly to receptor 11; bound TGF-P then allows the recruitment of receptor I into the ligand-receptor I1 complex, which results in receptor I phosphorylation and subsequent propagation of the signal, In this report, we focused on the expression of the receptors involved in the signal transduction, ie, type I and type I1 receptors, in hematopoietic progenitors.
Our results show that CD34' cells purified from normal blood or bone marrow as well as CD34+ cells from MMM patients express both TGF-P type I and type I1 receptors. However, whereas the expression level of TGF-P type I receptor is similar in CD34+ cells from normal donors or patients, gene expression for the binding type I1 receptor is significantly reduced in CD34' patients' cells. This decrease is correlated with a lower protein expression; actually, after immunostaining with an anti-TGF-P receptor I1 antibody, not only the labeling intensity per cell but especially the percentage of positive CD34' cells are sig- Because primitive CD34' cells have been described to be more sensitive to the antiproliferative effects of TGF-P than more mature cells:6 it could be suggested that TGF-P receptor expression may be downmodulated along the differentiation pathway. In this respect, the lower expression of TGF-P type I1 receptor we reported here in CD34+ cells from blood of MMM patients could result from a more mature stage of these peripheral cells compared with normal bone marrow CD34' cells. Indeed, it has been stated that CD34' cells from peripheral blood differ, at least in their phenotype profile, from CD34' cells found in bone marrow, with the presence of more differentiated subpopulation^^^^^' However, several observations do not argue for this hypothesis. First, the levels of multilineage-associated differentiation markers, such as CD34, CD38, and CD33 antigens, expressed on CD34' cells purified from the blood of patients are comparable to those observed on CD34' cells purified from the bone marrow of healthy subjects. Second, the percentage of granulomacrophagic (CFU-GM), erythroid (BFU-E), or mastocytic (CFU-Mast) colonies obtained from the in vitro differentiation (in semisolid medium) of CD34+ cells purified from MMM patients or normal bone marrow are comparable, but are distinct from that obtained with CD34' cells from normal peripheral blood (M.C. Le Bousse-KerdiBs et al, manuscript in preparation). Third, the expression level of TGF-P type I1 receptor transcript is higher in CD34+ cells purified from normal blood than in CD34+ cells from the blood of patients.
Our results show a strong correlation ( R = .85) between TGF-P1 and TGF-P type I1 receptor gene expression in CD34' cells purified from normal bone marrow but not in CD34' cells purified from patients ( R = .37). This finding would suggest that TGF-P type I1 receptor gene might be differentially regulated in normal and MMM CD34+ cells. For instance, in patients, the lower intensity of the TGF-P type 11 receptor immunostaining in CD34+ cells might be in favor of a downregulation of this receptor by TGF-P1 produced in large amount by other cell types, mainly of the megakaryocytic lineage.16 An alternative explanation would be that the alteration of TGF-P type I1 receptor in patients may be linked to the clonal origin of MMM CD34' cells. The possible relationship between the decrease of this TGF-P receptor and the clonal origin of CD34' is currently being studied in chimerical patients with easily detectable cytogenetic anomalies.
The apparent paradox between the quite normal (in CD34' cells) or increased (in PBMC) levels of TGF-P1 found in MMM patients and the myeloproliferation observed in the disease raises the question of an alteration of the sensitivity of patient CD34+ cells to TGF-P. The lower expression of the type I1 receptor, which is the ligand binding receptor, observed in these cells suggests that such a significant decrease in receptor expression could be part of the mechanism(s) allowing hematopoietic progenitors to escape from the negative regulation of TGF-P. Actually, results showing that, in liquid culture containing growth factors, the doubling time of hematopoietic cells resulting from CD34' progenitor proliferation ranges from 2.5 to 3 days in MMM patients, whereas it reaches 5 days in normal individuals, and that anti-TGF-P1 antibody treatment has a greater effect on normal than on MMM CD34' cell proliferation are in agreement with this hypothesis. bFGF is expressed by a variety of cell types, including stromal and hematopoietic cellsZo such as monocytes/macrophages,4' granulocytes, and, above all, megakaryocytes and platelets#; however, its presence in CD34' cells was still hypothetical. We show here that, although its expression is very low, bFGF transcript could be detected in RT-PCR products from CD34' cells purified from the bone marrow, but not from the blood, of some healthy donors. Moreover, bFGF expression is significantly higher in CD34'
progenitors from the majority of MMM patients. Such a higher expression of bFGF in patient CD34' cells is also observed at the protein level. FGF responses are triggered by the activation of receptors that are a family of structurally related transmembrane tyrosine kinases. At present, this family contains five member^^^.^^; among those members, the presence of receptor type I (flg) and type I1 (bek) has been shown in hematopoietic Although bFGF can elicit biologic effects on normal CD34' progenitor cells:' receptor expression in these cells has not been reported yet. Using RT-PCR analysis, the present results indicate that, in normal CD34' cells, the receptor type I transcript was undetectable or extremely low, whereas the receptor type I1 transcript could be more easily detected, at least in some samples. Interestingly, as for bFGF, we show that the gene and protein expression of its type I and type I1 receptors is significantly increased in the majority of MMM patients. Indeed, not only the bFGF RI and RI1 transcript levels, but also the intensity of immunolabeling and the percentage of CD34' expressing both receptor proteins are significantly higher in patients than in the normal subjects that express these molecules.
From these data, it could be speculated that the increased expression of bFGF together with the augmentation of its type I and type I1 receptors might be involved in the mechanism(s) allowing an enhanced myeloproliferation from CD34' progenitors in MMM patients. Although bFGF is devoid of secretory signal peptide5' and its secretion pathway is not as yet elucidated, a number of data have suggested that bFGF could have an autocrine role." Our results, which show the presence of bFGF and of highly expressed type 1 and type I1 receptors in patients' CD34+ cells, are in agreement with such an autocrine regulation mechanism; however, these findings do not rule out the possibility of both autocrine and paracrine mechanisms. Because bFGF by itself has been shown to be inefficient in stimulating hematopoietic progenitors,2'.z0 the increased CD34' proliferation in MMM patients might be related to the various properties of this peptide. First, bFGF can regulate early hematopoiesis not only by acting on progenitors in synergy with multilineage cytokines such as IL-3, GM-CSF, or SCF: ' but also by increasing the production of hematopoietic stimulating factors, especially IL-1 3o and CSF-1 ,' 2 by stromal cells. Second, bFGF may favor hematopoiesis by increasing the glycosaminoglycan (GAG) content of the extracellular matrix and, subsequently, the local concentration of growth factors." In this respect, it is relevant to notice that CSF-I 53 
